SBIR/STTR Research Award

Overcoming Isoniazid Resistance in Tuberculosis with New Chemical Entitites

Award identifier 81e4e6916cb3488f48dc007ddb1fb7183d695881ed32be8897084dd876752796Awarding agency Department of Health and Human Services · Centers for Disease Control and Prevention

Award amount

$187,500

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Centers for Disease Control and Prevention
Recipient company
SpinCeutica, Inc.
Proposal award date
2018-09-30
Contract end date
2019-03-29
UEI
VDTKVZHN6P79
Solicitation number
PA18-574
Topic code
NCHHSTP

Research abstract

Isoniazid resistance is a major problem worldwideespecially the high level resistance caused by ST KatG mutationWe have found a stable isotope substitution improves activity against this resistant strainwhile others have used long acyl hydrazides that also improve activityWe therefore hypothesize that combining long acyl chain hydrazides to drive ST KatG binding with our MIE enhancedacylC INH warhead will generate compounds even more potent at killing drug resistant tuberculosisTo test this hypothesis we propose the following aimsSpecific AimSynthesize and characterize a library of long acyl chain hydrazides ofacylC INH designed for additional binding modes to KatG based on INH CThis library will feature linear and branched chain alkanes fromtocarbons longand their biopharmaceutical properties will be determinedSpecific AimTest the libraries binding affinities to wild type and ST KatGtheir IN NAD adduct formation yieldstheir effects on INH sensitive and resistant Mtuberculosisand their toxicity in mammalian HepGcellsThis will provide the preliminary data to support later in vivo testing in a range of INH resistant strains of Mtuberculosis Project NarrativeIsoniazid is a mainstay of tuberculosis treatmentbut isoniazid resistance is a major problemWe are developing new isoniazid derivatives combining two new approaches to target isoniazidresistanceand enable better treatment of multidrug resistant tuberculosis

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2017–2020). Reported award amounts total $1,580,894. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.